Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Su Xu is active.

Publication


Featured researches published by Su Xu.


Molecular and Cellular Biology | 2005

The Absence of p53 Promotes Metastasis in a Novel Somatic Mouse Model for Hepatocellular Carcinoma

Brian C. Lewis; David S. Klimstra; Nicholas D. Socci; Su Xu; Jason A. Koutcher; Harold E. Varmus

ABSTRACT We have generated a mouse model for hepatocellular carcinoma using somatic delivery of oncogene-bearing avian retroviral vectors to the liver cells of mice expressing the viral receptor TVA under the control of the albumin gene promoter (Alb-TVA mice). Viruses encoding mouse polyoma virus middle T antigen (PyMT) induced tumors, which can be visualized with magnetic resonance imaging, in 65% of TVA-positive animals. While these tumors can exceed 10 mm in diameter, they do not invade locally or metastasize to the lungs. Delivery of PyMT-expressing viruses to Alb-TVA mice lacking an intact p53 gene does not increase tumor incidence. However, the resulting tumors are poorly differentiated, invasive, and metastatic to the lungs. Gene expression microarrays identified over 100 genes that are differentially expressed between tumors found in p53 wild-type and p53 null mice. Some of these genes, such as cathepsin E and Igf2, have been previously implicated in tumor cell migration and invasion. Tumors induced in p53 null, TVA transgenic mice by PyMT mutants with changes in specific tyrosine residues fail to form metastases, indicating that metastasis is dependent on both the oncogene and the absence of p53.


Magnetic Resonance in Medicine | 2003

In vivo multiple-mouse imaging at 1.5 T

Su Xu; T. Gade; Cornelia Matei; Kristen L. Zakian; Alan A. Alfieri; X. Hu; Eric C. Holland; S. Soghomonian; Juri Gelovani Tjuvajev; Douglas Ballon; Jason A. Koutcher

A multiple‐mouse solenoidal MR coil was developed for in vivo imaging of up to 13 mice simultaneously to screen for tumors on a 1.5 T clinical scanner. For the coil to be effective as a screening tool, it should permit acquisition of MRIs in which orthotopic tumors with diameters >2 mm are detectable in a reasonable period of time (<1 hr magnet time) and their sizes accurately measured. Using a spin echo sequence, we demonstrated that this coil provides sufficient sensitivity for moderately high resolution images (156–176 μm in plane‐resolution, 1.5 mm slice thickness). This spatial resolution permitted detection of primary brain tumors in transgenic/knockout mice and orthotopic xenografts. Brain tumor size as measured by MRI was correlated with size measured by histopathology (P < 0.001). Metastatic tumors in the mouse lung were also successfully imaged in a screening setting. The multiple mouse coil is simple in construction and may be implemented without any significant modification to the hardware or software on a clinical scanner. Magn Reson Med 49:551–557, 2003.


Brain Research | 2001

Fractionated radiation facilitates repair and functional motor recovery after spinal cord transection in rat

Nurit Kalderon; Su Xu; Jason A. Koutcher; Zvi Fuks

Previous studies suggest that motor recovery does not occur after spinal cord injury because reactive glia abort the natural repair processes. A permanent wound gap is left in the cord and the brain-cord circuitry consequently remains broken. Single-dose x-irradiation destroys reactive glia at the damage site in transected adult rat spinal cord. The wound then heals naturally, and a partially functional brain-cord circuitry is reconstructed. Timing is crucial; cell ablation is beneficial only within the third week after injury. Data presented here point to the possibility of translating these observations into a clinical therapy for preventing the paralysis following spinal cord injury in the human. The lesion site (at low thoracic level) in severed adult rat spinal cord was treated daily, over the third week postinjury, with protocols of fractionated radiation similar to those for treating human spinal cord tumors. This resulted, as with the single-dose protocol, in wound healing and restoration of some hindquarter motor function; in addition, the beneficial outcome was augmented. Of the restored hindlimb motor functions, weight-support and posture in stance was the only obvious one. Recovery of this motor function was partial to substantial and its incidence was 100% instead of about 50% obtained with the single-dose treatment. None of the hindlimbs, however, regained frequent stepping or any weight-bearing locomotion. These data indicate that the therapeutic outcome may be further augmented by tuning the radiation parameters within the critical time-window after injury. These data also indicate that dose-fractionation is an effective strategy and better than the single-dose treatment for targeting of reactive cells that abort the natural repair, suggesting that radiation therapy could be developed into a therapeutic procedure for repairing injured spinal cord.


PLOS ONE | 2017

Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer

Nina P. Connolly; Jesse A. Stokum; Craig S. Schneider; Tatsuya Ozawa; Su Xu; Rebeca Galisteo; Rudolph J. Castellani; Anthony J. Kim; J. Marc Simard; Jeffrey A. Winkles; Eric C. Holland; Graeme F. Woodworth

Previously rodent preclinical research in gliomas frequently involved implantation of cell lines such as C6 and 9L into the rat brain. More recently, mouse models have taken over, the genetic manipulability of the mouse allowing the creation of genetically accurate models outweighed the disadvantage of its smaller brain size that limited time allowed for tumor progression. Here we illustrate a method that allows glioma formation in the rat using the replication competent avian-like sarcoma (RCAS) virus / tumor virus receptor-A (tv-a) transgenic system of post-natal cell type-specific gene transfer. The RCAS/tv-a model has emerged as a particularly versatile and accurate modeling technology by enabling spatial, temporal, and cell type-specific control of individual gene transformations and providing de novo formed glial tumors with distinct molecular subtypes mirroring human GBM. Nestin promoter-driven tv-a (Ntv-a) transgenic Sprague-Dawley rat founder lines were created and RCAS PDGFA and p53 shRNA constructs were used to initiate intracranial brain tumor formation. Tumor formation and progression were confirmed and visualized by magnetic resonance imaging (MRI) and spectroscopy. The tumors were analyzed using histopathological and immunofluorescent techniques. All experimental animals developed large, heterogeneous brain tumors that closely resembled human GBM. Median survival was 92 days from tumor initiation and 62 days from the first point of tumor visualization on MRI. Each tumor-bearing animal showed time dependent evidence of malignant progression to high-grade glioma by MRI and neurological examination. Post-mortem tumor analysis demonstrated the presence of several key characteristics of human GBM, including high levels of tumor cell proliferation, pseudopalisading necrosis, microvascular proliferation, invasion of tumor cells into surrounding tissues, peri-tumoral reactive astrogliosis, lymphocyte infiltration, presence of numerous tumor-associated microglia- and bone marrow-derived macrophages, and the formation of stem-like cell niches within the tumor. This transgenic rat model may enable detailed interspecies comparisons of fundamental cancer pathways and clinically relevant experimental imaging procedures and interventions that are limited by the smaller size of the mouse brain.


The Journal of Nuclear Medicine | 2003

Pharmacokinetics and Biodistribution of 86Y-Trastuzumab for 90Y Dosimetry in an Ovarian Carcinoma Model: Correlative MicroPET and MRI

Stig Palm; Richard Enmon; Cornelia Matei; Katherine S. Kolbert; Su Xu; Pat Zanzonico; Ronald L. Finn; Jason A. Koutcher; Steven M. Larson; George Sgouros


The Journal of Nuclear Medicine | 2003

Murine S Factors for Liver, Spleen, and Kidney

Katherine S. Kolbert; Timotheus Watson; Cornelia Matei; Su Xu; Jason A. Koutcher; George Sgouros


Neoplasia | 2002

MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials.

Jason A. Koutcher; Xiaoyi Hux; Su Xu; T. Gade; Norman E. Leeds; Xiaohong Joe Zhou; David Zagzag; Eric C. Holland


The Journal of Urology | 2003

Detection and quantitative analysis of early stage orthotopic murine bladder tumor using in vivo magnetic resonance imaging

Eiji Kikuchi; Su Xu; Makoto Ohori; Cornelia Matei; Mihaela E. Lupu; Silvia Menendez; Jason A. Koutcher; Bernard H. Bochner


Cancer Research | 2017

Abstract 808: PDGF-A overexpression and p53 depletion in rat neural precursor cells induces large brain tumors that resemble human glioblastoma

Nina P. Connolly; Craig S. Schneider; Amol C. Shetty; Su Xu; Tatsuya Ozawa; Anthony J. Kim; Jeffrey A. Winkles; Eric C. Holland; Graeme F. Woodworth


Archive | 2003

Ovarian Carcinoma Model: Correlative MicroPET and MRI

Stig Palm; Richard Enmon; Cornelia Matei; Katherine S. Kolbert; Su Xu; Pat Zanzonico; Ronald L. Finn; Jason A. Koutcher; Steven M. Larson; George Sgouros

Collaboration


Dive into the Su Xu's collaboration.

Top Co-Authors

Avatar

Jason A. Koutcher

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Cornelia Matei

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Eric C. Holland

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Katherine S. Kolbert

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Richard Enmon

Memorial Sloan Kettering Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge